Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine-Reference-Cited by-同舟云学术

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine

Published:2019-03-03 Issue:4 Volume:185 Page:679-690
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Nahas Myrna R.¹^ORCID,Stroopinsky Dina¹^ORCID,Rosenblatt Jacalyn¹,Cole Leandra¹,Pyzer Athalia R.¹,Anastasiadou Eleni¹,Sergeeva Anna²,Ephraim Adam¹,Washington Abigail¹,Orr Shira¹,McMasters Malgorzata¹,Weinstock Matthew¹,Jain Salvia¹,Leaf Rebecca K.¹,Ghiasuddin Haider¹,Rahimian Maryam¹,Liegel Jessica¹,Molldrem Jeffrey J.²,Slack Frank¹,Kufe Donald³,Avigan David¹

Affiliation:

1. Beth Israel Deaconess Medical Center Harvard Medical School Boston MAUSA

2. The University of Texas MD Anderson Cancer Center Houston TX USA

3. Dana‐Farber Cancer Institute Department of Medical Oncology Boston MA

Funder

Astex Pharmaceuticals

WES (When Everyone Survives) Foundation

Dana-Farber Harvard Cancer Center (DFHCC) Leukemia Spore Career Enhancement Award

Publisher

Wiley

Subject

Hematology